
Beyond Biotech - the podcast from Labiotech
LabiotechAudio
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 35 minutes
- Latest episode:
About this show
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.
Covers: biotech, life sciences, gene therapy, drug discovery, obesity drugs, gene editing, biotech conferences, business development, neurology, diabetes treatment
Show details and episodes come from the publisher's public feed at rss.buzzsprout.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
Beyond Biotech is a weekly podcast from Labiotech covering news, breakthroughs and innovation in the life sciences industry, with expert interviews. Recent episodes cover gene editing pipelines, GLP-1 obesity and diabetes treatments, AI drug discovery, childhood myopia treatment, and partnering at BIO-Europe.
Cosmos
Similar in subject
- The Biotech Startups Podcast
Both cover: biotech, life sciences
Similar shows
Explore more
Episodes
The first PROTAC is here. What comes next in protein degradation?
· 35 min
Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine. Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone: the first PROTAC ever to succeed in a Phase 3 clinical trial, with a regulatory filing now in front of the FDA. - 01:19 Meet Randy Teel - 03:41 Stepping into the CEO role in February 2026 - 13:17 What is a PROTAC and how it works - 17:37 Vepdegestrant and the first PROTAC approval - 23:43 Balancing partnerships versus keeping control of assets - 31:57 Key milestones to watch in the next 12–18 months Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - From undruggable to oral therapy: The rise of STAT6 degraders (https://www.labiotech.eu/in-depth/stat6-degraders/) - Big Pharma Strikes Megadeals In Targeted Protein Degradation (https://www.labiotech.eu/trends-news/protein-degradation-dunad/) - This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins (https://www.labiotech.eu/startup-scout/polyprox-protacs-cancer-treatment/)
Not rated yetDe-risking neurology drug development with better mouse models
· 40 min
Today we welcome Brandy Wilkinson, CEO of GemPharmatech (https://en.gempharmatech.com), and Rikki Feng, the company’s Neuroscience Pipeline Leader. Our discussion focuses on a persistent challenge in drug development: neurology’s stubbornly high clinical failure rates. GemPharmatech is tackling this head-on with proprietary models for Alzheimer’s, Parkinson’s, and blood-brain barrier transport that better mirror human disease biology. We explore why mouse models matter more in neurology than in other fields, the design principles behind these next-generation tools, and how smarter preclinical partnerships can help therapeutic developers de-risk programs earlier. - 00:00 Welcome Brandy Wilkinson and Rikki Feng - 03:17 GemPharmatech's mission - 06:26 Why mouse models matter in neurology - 11:11 Common translation gaps in neurology - 18:09 Designing proprietary neurological disease models - 25:45 Building stronger CRO strategic partnerships - 33:58 An optimistic future of neuroscience research This episode was produced with the support of GemPharmatech (https://en.gempharmatech.com). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Neurological diseases R&D trends and breakthrough innovations (https://www.inpart.io/insights/neurological-diseases-trends-report) - Brain Awareness Week: could ongoing R&D spur neuroscience breakthroughs? (https://www.labiotech.eu/in-depth/brain-awareness-week-neuroscience-breakthroughs/) - 11 neuroscience biotech companies you should know about (https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/)
Not rated yetBIO International Convention 2026: practical advice from former Evotec CEO Werner Lanthaler
· 40 min
This week we preview the BIO International Convention, starting next week in San Diego. This is the key partnering event of the year where biotechs connect with pharmaceutical companies and investors in partnering meetings, all to advance and fund innovative therapies. My guest is Werner Lanthaler, Founder and CEO of WLAN Holding. Werner spent 15 years as CEO of Evotec SE, scaling the company from 200 employees and €40 million revenue to over 5,000 staff and €800 million. He previously served as CFO of Intercell AG, overseeing its IPO and vaccine launch and today he leads investments and advisory in high-tech life sciences. Werner explains why partnering events like BIO are critical to advancing science in biopharma. He shares practical advice on how biotechs can prepare before the event, succeed on site, and follow up to turn meetings into partnerships. He offers clear, actionable strategies to optimize your BIO experience. - 01:36 Meet Werner Lanthaler - 06:48 The power of partnering - 08:55 Uncovering unexpected value - 13:43 Irreplaceable in-person trust - 17:06 Smart pre-event planning - 21:00 Strategic targeting - 24:02 Relationship-first meetings - 30:18 The importance of prompt, persistent follow-up Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Special Episode: The 2025 BIO International Convention (https://podcast.labiotech.eu/1995493/episodes/17362500-special-episode-the-2025-bio-international-convention) - The ABC of biotech partnerships (https://www.labiotech.eu/expert-advice/biotech-partnership-types/) - How to optimize your biotech company for partnering, licensing, and business success (https://podcast.labiotech.eu/1995493/episodes/18821478-how-to-optimize-your-biotech-company-for-partnering-licensing-and-business-success)
Not rated yetAdvancing corticosteroids and hormonal therapies for supply and scale
· 27 min
Today we’re diving into the world of corticosteroids and hormonal therapies — essential APIs that treat everything from asthma and autoimmune diseases to diabetes and endocrine disorders. These molecules may be decades old, but their manufacturing remains highly complex and critical to patients worldwide. Our guest is Olivier Roux, a Senior Director at Curia. He shares how Curia partners with both startups and big pharma to simplify steroid API challenges, solve supply issues, and prepare for next-generation innovations. If you want to understand what it really takes to bring these life-changing therapies to patients, stay tuned — this conversation is packed with insights you won’t want to miss. - 01:39 Meet Olivier Roux - 02:20 What corticosteroids and hormonal therapies are - 04:40 Evolution of steroidal hormonal therapies - 05:50 Common uses of corticosteroids today - 07:40 Key drivers of market growth - 10:06 Curia’s agile outsourcing solutions for steroids - 16:05 Importance of particle size control for steroids - 17:18 Aseptic processing and high potency handling This episode was produced with the support of Curia (https://curiaglobal.com). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Eight rare autoimmune diseases biotechs are fighting to treat (https://www.labiotech.eu/in-depth/rare-autoimmune-diseases-biotech/) - A clearer path to relief: sinusitis treatments on the way (https://www.labiotech.eu/in-depth/emerging-sinusitis-treatments/) - Asthma study suggests lung scarring may be reversible (https://www.labiotech.eu/trends-news/lung-scarring-asthma/)
Not rated yetEpisode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
· 43 min
Welcome to episode 200! Today I’m delighted to welcome back a very special guest: Joachim Eeckhout, the co-founder of Labiotech, co-owner of Knowbio, and founder of The Science Marketer. Joachim tells the Labiotech story, one of vision, persistence, and a deep belief that the European life-sciences sector deserved better storytelling. We go back to the very beginning with someone who was there: the frustrations, a bike tour of France that became legendary, the leap to Berlin, the fundraising rounds, the acquisition, and the launch of this very podcast. We’ll also hear where Joachim is today with his new ventures, his candid take on the current biotech media landscape in Europe, and what he sees coming next for science communication and media in our industry. - 01:30: Meet Joachim Eeckhout - 02:19: Early attraction to media creation - 04:32: Founding story of Labiotech platform - 06:35: Bike tour visiting biotech CEOs - 11:21: Identifying larger European market opportunity - 19:55: Raising seed funding for growth - 24:20: Acquisition by Inpart in 2021 - 30:48: Current work with Knowbio - 38:57: Future plans for Knowbio and biotech media Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Connecting the R&D ecosystem: 150 days into the integration of Inova, IN-PART and Labiotech (https://www.labiotech.eu/inside-labiotech/connecting-the-rd-ecosysteme-labiotech-inova-inpart/) - We raised our second financing round to become the largest biotech media 🚀 (https://www.labiotech.eu/inside-labiotech/press-release-fundraising-labiotech-second/) - How you can get involved in helping the industry–academia community solve global challenges (https://www.labiotech.eu/inside-labiotech/get-involved-in-helping-the-industry-academia-community-solve-global-challenges/)
Not rated yetWorld MS Day Special: Immunic reveals new hope for progressive MS
· 27 min
Today we welcome Dr. Daniel Vitt, CEO of Immunic Therapeutics (https://imux.com). With World MS Day (https://worldmsday.org)being tomorrow, the 30th of May, this is the perfect moment to focus on multiple sclerosis — a disease that affects nearly three million people worldwide and still leaves many patients searching for better options. In today’s episode Daniel shares his own journey into biotechnology, walk us through what life with MS really looks like for patients, and explain the science behind Immunic’s most advanced program, IMU-838. We discuss what makes Immunic’s oral therapy different from today’s treatments, uncover the latest data from the CALLIPER and ENSURE trials, and talk about what the future of MS care could look like. - 01:22 Meet Daniel Vitt - 04:54 Understanding multiple sclerosis - 07:53 Evolution of the MS treatment landscape - 12:08 Immunic’s lead MS therapy explained - 22:57 World MS Day and what's next for Immunic Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - 11 neuroscience biotech companies you should know about (https://www.labiotech.eu/best-biotech/neuroscience-biotech-companies/) - The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval (https://www.labiotech.eu/in-depth/btk-inhibitors-multiple-sclerosis-treatment/) - Six biotech companies advancing multiple sclerosis therapies (https://www.labiotech.eu/best-biotech/multiple-sclerosis-companies/)
Not rated yetThe problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
· 38 min
Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio (https://www.ochre-bio.com), a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen (https://www.lexogen.com), an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI data 15:47: How the Ochre-Lexogen partnership began 17:17: Why a specialist partner is essential for scale 18:21: Lexogen delivers on the massive sequencing project 21:50: Why high quality data is crucial 27:02: Lexogen's role in AI discovery 34:51: Future plans and directions This episode was produced with the support of Lexogen (https://www.lexogen.com). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Deep phenotyping brings accuracy to precision medicine (https://www.labiotech.eu/in-depth/precision-medicine-deep-phenotyping/) - Spatial Transcriptomics: A window into disease (https://www.labiotech.eu/in-depth/spatial-transcriptomics/) - Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions (https://www.labiotech.eu/trends-news/spatial-transcriptomics-readcoor-10x/)
Not rated yetFreeze variability, not progress: strengthen your cell therapy supply chain from the start
· 30 min
Today, we're digging into a topic that's getting a lot more attention lately, how early decisions in cell therapy end up shaping or complicating everything that comes later. Our episode today is Freeze Variability, Not Progress, How to Strengthen Your Cell Therapy Supply Chain from the Start, and we're going to challenge a few long-held beliefs about how starting material should be handled. My guest today is Dominic Clarke, Vice President of Technical Operations for IntegriCell at Cryoport Systems (https://www.cryoport.com). Dominic has spent years in the trenches building and scaling cell therapy processes from early development through commercialization. So, he's seen where things break and what actually works. I hope you enjoy my conversation with Dominic Clark. - 01:07 Meet Dominic Clarke and Cryoport Systems - 06:24 Fresh cells versus frozen cells - 08:21 Why teams switch to cryopreservation late - 12:37 The challenge of variability - 16:47 IntegriCell when you already have a process in place - 22:17 An argument for cryopreservation based on data - 25:56 The future of IntegriCell and Cryoport Systems This episode is brought to you with the support of Cryoport Systems (https://www.cryoport.com). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - IntegriCell® Cryopreservation (https://www.cryoport.com/solutions/integricell/) - Cryoport Systems on the state of the ATMP market and the importance of supply chain resilience (https://www.buzzsprout.com/1995493/episodes/17557893) - Cracking the code: Delivering biotherapeutics successfully across EMEA (https://www.labiotech.eu/partner/delivering-biotherapeutics-emea-cryoport/)
Not rated yetMaking labs smarter for scientific breakthroughs
· 30 min
Today, we dive into the future of lab management with Ryan Cawood, CEO and co-founder of Lab Thread (https://www.labthread.com/?utm_source=labiotech&utm_medium=affiliate&utm_campaign=podcast). Ryan's journey spans groundbreaking work in virotherapy and gene delivery during his D.Phil at Oxford, to founding OXGENE, a cell and gene therapy innovator acquired by WuXi Advanced Therapies in 2021. We'll explore the frustrations of fragmented lab tools that inspired Lab Thread's integrated digital solution—combining ELN, LIMS, molecular biology, and collaboration in one seamless platform. We’ll uncover how it boosts reproducibility, ensures compliance, and frees scientists for innovation, with accessible pricing for academics and biotechs. I hope you enjoy Ryan’s insights on evolving digital workflows and accelerating breakthroughs in the lab. 01:51: Meet Ryan Cawood 02:31: Frustrations with early digital tools. 03:19: Daily lab organization challenges. 06:50: Time lost to admin tasks. 11:09: Genesis of the Lab Thread concept. 13:53: Integrated workflow functionality explained. 17:23: Enhancing experiment reproducibility methods. 20:37: Achieving compliance standards easily. 26:10: The future of digital lab management. 28:33: Accelerating scientific breakthroughs. This episode is brought to you with the support of Lab Thread (https://www.labthread.com/?utm_source=labiotech&utm_medium=affiliate&utm_campaign=podcast). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Lab Thread - Your Lab, Connected (https://www.labthread.com/?utm_source=labiotech&utm_medium=affiliate&utm_campaign=podcast) - Hiding in plain sight: how to solve bioscience’s software problem (https://www.labiotech.eu/opinion/synthace-biosciences-software-problem/) - Lab chaos and digital dreams (https://www.labthread.com/blog/lab-chaos-and-digital-dreams-the-journey-to-lab-thread)
Not rated yetHow Epicrispr is leveraging CRISPR without cutting DNA
· 33 min
This week we dive into the Beyond Biotech archive to bring you a discussion with Dr Stanley Qi, the founder of Epicrispr. Epicrispr is an epigenetic editing company, leveraging the power of CRISPR without cutting DNA. The company’s proprietary Gene Expression Modulation System (GEMS) includes the smallest Cas protein known to work in human cells, enabling in vivo or ex vivo delivery via a single viral vector. In this episode we discuss epigenetic editing, why it’s reversible, and how it can treat FSHD and other conditions. - 01:43 Meet Stanley Qi - 03:32 Founding Epicrispr - 05:53 CRISPR interference and epigenome explained - 10:04 Overview of GEMS gene modulation system - 11:28 Reversibility and safety of epigenetic edits - 18:42 Strategy for tackling multiple disease conditions - 23:27 Clinical trial plans for EPI-321 candidate - 30:06 Looking forward This episode is brought to you with the support of MedChemExpress. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Could CRISPR really cure these diseases? (https://www.labiotech.eu/in-depth/crispr-technology-cure-disease/) - 10 gene therapy companies you should know about (https://www.labiotech.eu/best-biotech/gene-therapy-companies/) - CRISPR technology’s next wave: Ten companies to watch (https://www.labiotech.eu/best-biotech/crispr-companies/)
Not rated yetDiagonal Therapeutics’ innovative clustering antibodies for vascular diseases
· 31 min
Today we’re joined by Patrick Andre, Chief Scientific Officer at Diagonal Therapeutics. A trained vascular biologist, Patrick’s career spans groundbreaking work at Pfizer, Acceleron, Pliant Therapeutics, and earlier companies, where he focused on TGF-β superfamily signaling and receptor pathways that keep blood vessels healthy. Now at Diagonal, he’s leading a bold mission: developing clustering antibodies that correct the root cause of serious genetic vasculopathies, rather than just managing symptoms. In this episode, Patrick walks us through his personal journey into science, the company’s DIAGONAL platform, and their lead program DIAG723, which recently received Orphan Drug Designation for the rare disease HHT, and is advancing toward the clinic. We also discuss Diagonal’s oversubscribed $125 million Series B financing that closed in January 2026, and what clustering antibodies could mean for patients with HHT, pulmonary arterial hypertension, and beyond. - 01:33 Meet Patrick Andre - 08:01 Diagonal’s mission - 11:39 What are clustering antibodies - 16:05 Receptor clustering benefits for HHT and PAH - 20:24 Preclinical data on preventing and reversing HHT pathology - 22:39 The impact of the $125 Million Series B financing round Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Vaderis emerges from stealth to start HHT trial (https://www.labiotech.eu/trends-news/vaderis-therapeutics-hht-trial/) - Pulmonary hypertension after Winrevair: where GSK’s $950M bet fits (https://www.labiotech.eu/in-depth/hs235-gsk-next-gen-pulmonary-hypertension-drug/) - New treatment for pulmonary hypertension: what biotech holds in store? (https://www.labiotech.eu/in-depth/new-pulmonary-hypertension-treatments/)
Not rated yetArgobio: the venture model building Europe’s next biotech champions
· 42 min
Our guest today is Thierry Laugel, Managing Partner of Kurma & Chairman of Argobio. With a PharmD, PhD in pharmacology, and an INSEAD MBA, Thierry has spent more than two decades bridging cutting-edge science and commercial success—first in pharma R&D, then as co-founder of Kurma Partners, and now leading Argobio’s unique venture-builder model. Since raising €50 million in 2021, Argobio has co-founded and accelerated several companies from top European academic labs. Three of them—Enodia, Laigo Bio, and Elkedonia—have already closed seed rounds totaling more than €43 million, advancing novel platforms in targeted protein degradation, precision membrane protein degraders, and non-hallucinogenic neuroplasticity enhancers for depression. Thierry shares how Argobio reduces execution risk, embeds operational expertise, and turns promising science into investable companies that can compete worldwide. - 04:02 Blending pharmacology expertise with business - 07:50 Vision behind starting Kurma Partners - 12:53 Launching Argobio to address gaps in European biotech - 17:40 What makes the Argobio operational venture builder model unique - 25:02 Criteria for selecting academic scientific breakthroughs - 27:34 Changing dynamics of commercializing European research - 35:30 Europe vs US biotech investment climates - 37:47 Role of venture studios in Europe’s biotech future Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - M Ventures: pharma CVC and biotech innovation in 2026 (https://podcast.labiotech.eu/1995493/episodes/18453766-m-ventures-pharma-cvc-and-biotech-innovation-in-2026) - Inside Flagship Pioneering's strategy: How this VC turns ideas into biotech giants (https://podcast.labiotech.eu/1995493/episodes/17108243-inside-flagship-pioneering-s-strategy-how-this-vc-turns-ideas-into-biotech-giants) - Venture capital co-creation: The next big thing in biotech investment? (https://podcast.labiotech.eu/1995493/episodes/16441913-venture-capital-co-creation-the-next-big-thing-in-biotech-investment)
Not rated yetMulti-agent AI delivers reliable and scalable insights for single-cell omics
· 43 min
Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data. Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics (https://www.nygen.io), a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery. Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success. - 01:00 Meet Parashar Dhapola - 05:45 AI in biopharma - 09:29 AI automation vs. new capabilities - 11:28 What makes single-cell omics data different - 18:46 Risks of incorrect cell annotation - 34:37 Future of single-cell analytics This episode is produced with the support of Nygen Analytics (https://www.nygen.io). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - CyteType - AI powered cell type annotation (https://www.nygen.io/products/cytetype) - Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure? (https://www.labiotech.eu/trends-news/cure51-nvidia-deal-biotech/) - The past, present, and future of genome sequencing (https://www.labiotech.eu/in-depth/genome-sequencing/)
Not rated yetNionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight
· 28 min
This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio (https://nionyxbio.com), just days after the company took first place in the BIO-Europe Spring Startup Spotlight (https://informaconnect.com/bioeurope-spring/startup-spotlight/) competition in Lisbon. With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx’s proprietary AAV capsid platform and Kidney Atlas, what it took to win the Startup Spotlight, and what the victory means for the young company’s future. · 01:25 – Meet Magdalena Tyrpien · 07:10 – The Nionyx mission · 15:29 – The 2026 BIO-Europe Spring Startup Spotlight · 22:23 – Looking forward and future milestones Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026 (https://www.labiotech.eu/partner/bio-europe-startup-spotlight-lisbon-2026/) - BIO-Europe Spring 2026: partnership event brings funding hope to biotechs (https://www.labiotech.eu/in-depth/bio-europe-spring-2026/) - BIO-Europe partnering: Australian biotech companies share their experiences (https://www.labiotech.eu/trends-news/bio-europe-partnering-australian-biotech-lessons/)
Not rated yetHaemaLogiX - precision immunotherapy for multiple myeloma
· 43 min
Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX (https://haemalogix.com), an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders. HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field. Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year. - 01:15 Meet Rosanne Dunn - 07:52 HaemalogiX's mission and novel antigens - 09:53 Overview of multiple myeloma and its symptoms - 12:19 Targeting malignant plasma cells while sparing normal ones - 19:25 Recent Peer-Reviewed Research - 26:08 Synergy with IMiDs like Revlimid - 29:08 Potential patient impact and quality of life - 35:05 Planned IPO in 2026 and funding needs Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - 5 cancers that immunotherapy can cure (https://www.labiotech.eu/best-biotech/cancers-immunotherapy-cure/) - BIO-Europe partnering: Australian biotech companies share their experiences (https://www.labiotech.eu/trends-news/bio-europe-partnering-australian-biotech-lessons/) - How are R&D Tax Incentives shaping Australia’s biotech future? (https://www.labiotech.eu/in-depth/rd-tax-incentive-biotech-boost-australia/)
Not rated yetHow Leyden Labs is revolutionizing flu protection with its intranasal antibody spray
· 32 min
Today we welcome Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs (https://leydenlabs.com), and Clarissa Koch, the company's Chief Scientific Officer. Leyden Labs is pioneering a revolutionary non-vaccine approach to combat respiratory viruses like influenza and coronaviruses. Recently, they published groundbreaking data in Science Translational Medicine (https://www.science.org/doi/10.1126/scitranslmed.adz1580), demonstrating that their intranasal antibody spray is safe, well-tolerated, and delivers sustained protection right at the virus's entry point: the nose. This innovation addresses the shortcomings of traditional flu vaccines, which average just 13% effectiveness against infection and provide even less for vulnerable groups like the elderly and immunocompromised. We'll dive into the science, the company's journey since its 2020 founding, and their recent €50 million European funding boost amid U.S. biotech challenges. 01:33: Meet Koenraad Wiedhaup 03:13: Meet Clarissa Koch 04:16: Leyden Labs' origin story 06:21: Mucosal protection platform explained 08:57: Complementing existing vaccines 11:47: Science of mucosal immunity 13:24: PanFlu lead candidate overview 16:42: Key findings from recent publication 22:02: Funding and future preparedness Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Seven biotech companies to know in the Netherlands (https://www.labiotech.eu/best-biotech/biotech-companies-the-netherlands/) - The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 (https://www.labiotech.eu/in-depth/the-netherlands-biotech-hub/) - Influenza solution deals pile up as pandemic preparedness increases (https://www.labiotech.eu/trends-news/influenza-deals-surge/)
Not rated yetHow to optimize your biotech company for partnering, licensing, and business success
· 42 min
Today, we welcome Janita Good, a Partner at Fieldfisher (https://www.fieldfisher.com/en/sectors/life-sciences) with nearly two decades of experience advising top organizations in pharmaceuticals, biotechnology, and medical devices. With a D.Phil. in Biochemistry from the University of Oxford, Janita brings a unique blend of scientific insight and legal expertise to her work on venture investments, joint ventures, partnerships, and M&A deals. She's advised on landmark transactions, including funding rounds for Phynova and MedAnnex, and collaborations like Intelligent Ultrasound's AI imaging partnerships. In this episode, Janita shares practical guidance for biotech leaders on timing partnerships with larger pharma companies, planning for commercialization from the start, balancing optimistic fundraising with realistic deal projections, and avoiding common legal pitfalls in M&A. We'll also look ahead to emerging trends in the sector and talk through the best way to structure a company for tax effective partnering and licensing. 01:29: Meet Janita Good 04:42: Fieldfisher's life sciences focus 07:20: Fieldfisher’s differentiated approach 09:41: Timing early partnering discussions 17:26: Structuring for efficient deals 21:36: Planning commercialization from start 25:22: Key early legal considerations 30:00: Balancing fundraising and realism 36:25: Optimism in the biotech industry Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - How biotech startups become unicorns (https://www.labiotech.eu/expert-advice/how-to-become-a-biotech-unicorn/) - The ABC of biotech startup funding (https://www.labiotech.eu/expert-advice/biotech-startup-funding/) - Biotech’s legal storm: Why securities class action lawsuits are surging (https://www.labiotech.eu/in-depth/biotech-lawsuits/)
Not rated yetReversing tumor immunosuppression with next-gen GPCR modulation
· 34 min
Today we’re joined by Sean MacDonald, CEO of Kainova Therapeutics (https://www.kainovatx.com/en/). With more than twenty years of biotech leadership and deep expertise in strategy and development, Sean is guiding the company through an exciting new chapter. We’ll dive into Kainova’s innovative GPCR-modulating platform, its promising pipeline, the science behind reversing tumor immunosuppression and targeting inflammation, and the reasons behind the recent rebrand from Domain Therapeutics to Kainova Therapeutics. We’ll also be taking a look at the broader oncology landscape—what’s hot, who’s investing big, and where the biggest opportunities and challenges lie. 01:09 – Meet Sean Macdonald 05:40 – Kainova's GPCR platform and therapeutic focus 08:57 – The story and meaning behind the Kainova rebrand 10:25 – Series B funding and pipeline programs 16:43 – Exciting trends and innovations in oncology 29:17 – Upcoming milestones and future plans Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - GPCR therapies: Eight promising biotechs hacking the cell signaling pathway (https://www.labiotech.eu/best-biotech/gpcr-therapies-eight-promising-biotechs-bolstering-rd/) - Episode 182: Building a smart oncology pipeline with Cumulus Oncology (https://podcast.labiotech.eu/1995493/episodes/18577193-building-a-smart-oncology-pipeline-with-cumulus-oncology) - Episode 34: eClinical Solutions, GPCR Therapeutics, Orbsen Therapeutics (https://podcast.labiotech.eu/1995493/episodes/12272139-beyond-biotech-podcast-34-eclinical-solutions-gpcr-therapeutics-orbsen-therapeutics)
Not rated yetMisinformation is a public health crisis - here's how to fix it
· 50 min
Our guest is Sergey Jakimov, the Founding and Managing Partner of LongeVC (https://longevc.com), a venture capital firm dedicated to backing early-stage biotech and longevity startups. A serial entrepreneur, Sergey has co-founded ventures like Longenesis, a medical tech startup unlocking biomedical data for drug discovery, and the Longevity Science Foundation, a non-profit advancing healthy human lifespan. He’s been named to Forbes Latvia's 30 Under 30 in technology and healthcare, and via LongeVC, he invests in innovation in areas including therapeutics, diagnostics, and personalized medicine. In this episode, Sergey warns about the rising danger of misinformation disguised as health advice—where influencers and hype outpace evidence-based science. I hope you enjoy our discussion as we unpack this public health challenge and explore solutions for a more credible biotech landscape. - 01:22 Meet Sergey Jakimov - 06:14 Developing a longevity focus - 10:47 A typical day at LongeVC - 13:26 The LongeVC portfolio - 17:28 Misinformation as health crisis - 26:04 The harm of bad advice - 33:16 The impact on biotech industry funding - 36:18 Strategies for addressing misinformation - 42:17 Optimism about trends in longevity Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - 13 anti-aging startups on a mission to extend lives (https://www.labiotech.eu/best-biotech/anti-aging-biotech-companies/) - Turning back time with cellular reprogramming: Shift raises $16 million in seed funding (https://www.labiotech.eu/trends-news/cellular-reprogramming/) - Are European biotech VCs under pressure to scale? Time to get pragmatic (https://www.labiotech.eu/trends-news/european-biotech-vc/)
Not rated yetAccelerating rare disease cures with ASOs, gene editing, and AI
· 48 min
Today, we're joined by Professor Matthew Wood, a leading figure in neuroscience and RNA-based therapeutics. He is Professor of Neuroscience at the University of Oxford, Deputy Head of the Medical Sciences Division, and Director of both the MDUK Oxford Neuromuscular Centre and the Oxford-Harrington Rare Disease Centre, (https://www.oxfordharrington.org) a groundbreaking partnership between the University of Oxford and Harrington Discovery Institute dedicated to accelerating therapies for rare genetic diseases affecting millions worldwide. In today’s episode we discuss his vision for making antisense oligonucleotides (or ASOs) and gene editing more modular, more scalable, and faster by collaborating with regulators, scientists, and patient groups to bring hope to those with rare neuromuscular and genetic conditions. With rare disease day (https://www.rarediseaseday.org) coming up just next week, I hope you enjoy the insights that Professor Wood shares on the future of the fight against rare disease. 01:23 – Meet Matthew Wood 07:26 – The Oxford-Harrington Rare Disease Centre 10:33 – Collaborations, philanthropy, and industry partnerships 13:55 – Key challenges in rare disease therapy development 20:00 – Modular and scalable platforms for ASOs 28:08 – Scaling gene editing like CRISPR for rare diseases 32:38 – Role of AI and computational tools in acceleration 37:28 – Future breakthroughs in rare disease treatments 44:07 – Advice for new researchers in the field Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast) Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast) To dive deeper into the topic: - Prader Willi syndrome: five much-anticipated therapies poised for approval (https://www.labiotech.eu/in-depth/prader-willi-syndrome-anticipated-treatments/) - First-ever approval for Barth Syndrome treatment: what does this mean for ultra-rare disease therapeutics? (https://www.labiotech.eu/trends-news/elamipretide-fda-approval-ultra-rare-disease/) - When rare diseases are not so rare after all: A closer look at where and why this happens (https://www.labiotech.eu/in-depth/rare-disease-prevalence-population-genetics/)
Not rated yet